This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HQY vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
HQY vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the latest trading session, Medpace (MEDP) closed at $339.38, marking a +1.08% move from the previous day.
Medpace (MEDP) Stock Moves -1.52%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Medpace (MEDP) closed at $349.87, indicating a -1.52% shift from the previous trading day.
SGRY or MEDP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SGRY vs. MEDP: Which Stock Is the Better Value Option?
3 Reasons Growth Investors Will Love Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Medpace (MEDP) Tops Q2 Earnings Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 9.13% and 0.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
by Zacks Equity Research
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
Top Stocks to Buy for Growth as Earnings Approach
by Shaun Pruitt
Investors will want to pay attention to several top-rated Zacks stocks that are set to report their quarterly results on Monday, July 22.
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SGRY vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
SGRY vs. MEDP: Which Stock Is the Better Value Option?
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Medpace (MEDP) settling at $443, representing a +1.84% change from its previous close.
Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?
by Zacks Equity Research
Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.
Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial
by Zacks Equity Research
Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.
Medpace (MEDP) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hyperfine (HYPR) Inks New Partnerships to Expand in Europe
by Zacks Equity Research
Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.
STERIS (STE) AST Business Expands, New Offerings Aid Growth
by Zacks Equity Research
STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Illumina (ILMN) Buys Fluent, Grows in Single Cell Research
by Zacks Equity Research
By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
by Zacks Equity Research
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.
Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan
by Zacks Equity Research
Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region???s semiconductor manufacturing hub.
Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues
by Zacks Equity Research
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership
by Zacks Equity Research
QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.